Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes is a series of Editorials which is published on a biannual basis by the Editorial Board of the Medicinal Chemistry section of the journal Molecules [...].

Cancer Drug Resistance Group IPATIMUP Institute of Molecular Pathology and Immunology of the University of Porto Rua Júlio Amaral de Carvalho 45 4200 135 Porto Portugal

Department of Agricultural Sciences University of Naples Federico 2 80055 Portici Italy

Department of Analytical Chemistry Faculty of Natural Sciences Comenius University Ilkovicova 6 84215 Bratislava Slovakia

Department of Biological Sciences FFUP Faculty of Pharmacy University of Porto Rua de Jorge Viterbo Ferreira 228 4050 313 Porto Portugal

Department of Biotechnology chemistry and pharmacy University of Siena via Aldo Moro 2 53100 Siena Italy

Department of Chemistry National and Kapodistrian University of Athens Panepistimiopolis 15771 Athens Greece

Department of Drug Sciences Medicinal Chemistry and Pharmaceutical Technology Section University of Pavia Viale Taramelli 12 27100 Pavia Italy

Department of Nutrition Food Sciences and Gastronomy Faculty of Pharmacy and Food Sciences Institute of Biomedicine University of Barcelona Av Prat de la Riba 171 E 08921 Santa Coloma de Gramenet Spain

Department of Pharmaceutical Chemistry School of Pharmacy Faculty of Health Sciences Aristotle University of Thessaloniki 54124 Thessaloniki Greece

Department of Pharmacology and Neuroscience University of North Texas Health Science Center 3500 Camp Bowie Blvd Fort Worth TX 76107 USA

Department of Pharmacology and Toxicology and Department of Chemistry and Biochemistry College of Pharmacy The University of Arizona Biological Sciences West Room 351 1041 East Lowell Street Tucson AZ 85721 USA

Department of Pharmacy Health and Nutritional Sciences University of Calabria 1 87036 Arcavacata di Rende Italy

Department of Pharmacy University of Naples Federico 2 Via Mezzocannone 16 80134 Napoli Italy

Department of Pharmacy University of Pisa Via Bonanno 6 56126 Pisa Italy

Department of Sciences University of Basilicata Viadell'Ateneo Lucano 10 85100 Potenza Italy

Discipline of Clinical Pharmacology College of Medicine and Public Health Flinders University and Flinders Medical Centre Bedford Park SA 5042 Australia

Formerly head of the Department of Organic Chemistry University of Mons UMONS 7000 Mons Belgium

i3S Instituto de Investigação e Inovação em Saúde Universidade do Porto Rua Alfredo Allen 208 4200 135 Porto Portugal

ICOA CNRS UMR 7311 Universite d'Orleans Rue de Chartres 45067 Orleans CEDEX 2 France

Institute of NeuroPhysiopathology UMR 7051 Faculté de Médecine Secteur Nord 51 Boulevard Pierre Dramard CS80011 13344 Marseille CEDEX 15 France

Interdisciplinar de Investigação Marinha e Ambiental Universidade do Porto Terminal de Cruzeiros do Porto de Leixões Avenida General Norton de Matos S N 4450 208 Matosinhos Portugal

Laboratório de Química Orgânica e Farmacêutica Departamento de Ciências Químicas Faculdade de Farmácia Universidade do Porto Rua Jorge Viterbo Ferreira 228 4050 313 Porto Portugal

Laboratory of Pharmaceutical Chemistry Faculty of Pharmacy and Food Sciences and Institute of Biomedicine University of Barcelona Av Joan XXIII 27 31 E 08028 Barcelona Spain

LAQV REQUIMTE Departamento de Química e Bioquímica Faculdade de Ciências da Universidade do Porto Rua do Campo Alegre 687 4169 007 Porto Portugal

Pharmaceutical and Medicinal Chemistry Department Faculty of Pharmacy Al Quds University POB 20002 Jerusalem Palestine

Pharmaceutical Institute University of Bonn An der Immenburg 4 53115 Bonn Germany

Regional Centre of Advanced Technologies and Materials Faculty of Science Palacky University Slechtitelu 27 78371 Olomouc Czech Republic

Rome Center for Molecular Design Department of Drug Chemistry and Technology Sapienza University of Rome P le Aldo Moro 5 00185 Rome Italy

School of Pharmacy Faculty of Health Sciences University of Eastern Finland P O Box 1627 FI 70211 Kuopio Finland

School of Pharmacy Keele University Hornbeam building Staffordshire ST5 5BG UK

State Key Laboratory of Drug Research Shanghai Institute of Materia Medica Chinese Academy of Sciences 555 Zu Chong Zhi Road Shanghai 201203 China

Zobrazit více v PubMed

Kalkman D.N., Aquino M., Claessen B.E., Baber U., Guedeney P., Sorrentino S., Vogel B., de Winter R.J., Sweeny J., Kovacic J.C., et al. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. Eur. Heart J. 2018;39:4101–4108. doi: 10.1093/eurheartj/ehy633. PubMed DOI

Hersberger M. Potential role of the lipoxygenase derived lipid mediators in atherosclerosis: Leukotrienes, lipoxins and resolvins. Clin. Chem. Lab. Med. 2010;48:1063–1073. doi: 10.1515/CCLM.2010.212. PubMed DOI

Pettersen D., Broddefalk J., Emtenas H., Hayes M.A., Lemurell M., Swanson M., Ulander J., Whatling C., Amilon C., Ericsson H., et al. Discovery and early clinical development of an inhibitor of 5-lipoxygenase activating protein (AZD5718) for treatment of coronary artery disease. J. Med. Chem. 2019;62:4312–4324. doi: 10.1021/acs.jmedchem.8b02004. PubMed DOI

Sexton T.R., Zhang G., Macaulay T.E., Callahan L.A., Charnigo R., Vsevolozhskaya A., Li Z., Smyth S. Ticagrelor reduces thromboinflammatory markers in patients with pneumonia. JACC Basic Transl. Sci. 2018;3:435–449. doi: 10.1016/j.jacbts.2018.05.005. PubMed DOI PMC

Lancellotti P., Musumeci L., Jacques N., Servais L., Goffin E., Pirotte B., Oury C. Antibacterial activity of ticagrelor in conventional antiplatelet dosages against antibiotic-resistant Gram-positive bacteria. JAMA Cardiol. 2019 May 8; doi: 10.1001/jamacardio.2019.1189. PubMed DOI PMC

Ndagi U., Mhlongo N., Soliman M.E. Metal complexes in cancer therapy – an update from drug design perspective. Drug Des. Dev. Ther. 2017;11:599–616. doi: 10.2147/DDDT.S119488. PubMed DOI PMC

Starha P., Travnicek Z., Dvorak Z. A cytotoxic tantalum(V) half-sandwich complex: A new challenge for metal-based anticancer agents. Chem. Commun. 2018;54:9533–9536. doi: 10.1039/C8CC05223A. PubMed DOI

Travnicek Z., Starha P., Cajan M., Dvorak Z. A half-sandwich TaV dichlorido complex containing an O,N,O′-tridentate Schiff base ligand: Synthesis, crystal structure and in vitro cytotoxicity. Acta Cryst. 2019;C75:248–254. PubMed

Starha P., Travnicek Z., Dvorak Z. Dichloro-complexes of tantalum, method of their preparation and their use in preparation of drugs for cancer treatment. CZ 307 696 B6. 2019 Jan 9;

de Oliveira Pedrosa M., Duarte da Cruz R.M., de Oliveira Viana J., de Moura R.O., Ishiki H.M., Barbosa Filho J.M., Diniz M.F., Scotti M.T., Scotti L., Bezerra Mendonca F.J. Hybrid Compounds as Direct Multitarget Ligands: A Review. Curr. Top. Med. Chem. 2017;17:1044–1079. doi: 10.2174/1568026616666160927160620. PubMed DOI

Thi T.H.N., Thi Y.T., Nguyen L.A., Vo B.N., Ngo Q.A. Design, Synthesis and Biological Activities of New Pyrazole Derivatives Possessing Both Coxib and Combretastatins Pharmacophores. Chem. Biodivers. 2019 Apr 11; doi: 10.1002/cbdv.201900108. PubMed DOI

Lee M.J., Bhattarai D., Yoo J., Miller Z., Park J.E., Lee S., Lee W., Driscoll J.J., Kim K.B. Development of novel epoxyketone-based proteasome inhibitors as a strategy to overcome cancer resistance to carfilzomib and bortezomib. J. Med. Chem. 2019;62:4444–4455. doi: 10.1021/acs.jmedchem.8b01943. PubMed DOI PMC

Koldysheva E., Men’shchikova A., Lushnikova E., Popova N., Kaledin V., Nikolin V., Zakharenko A., Luzina O., Salakhutdinov N., Lavrik O. Antimetastatic activity of combined topotecan and tyrosyl-DNA phosphodiesterase-1 inhibitor on modeled lewis lung carcinoma. Bull. Exp. Biol. Med. 2019;166:661–666. doi: 10.1007/s10517-019-04413-3. PubMed DOI

Strøm M.B., Haug B.E., Skar M.L., Stensen W., Stiberg T., Svendsen J.S. The pharmacophore of short cationic antibacterial peptides. J. Med. Chem. 2003;46:1567–1570. doi: 10.1021/jm0340039. PubMed DOI

Boullet H., Bentot F., Hequet A., Ganem-Elbaz C., Bechara C., Pacreau E., Launay P., Sagan S., Jolivalt C., Lacombe C., et al. Small antiMicrobial peptide with in vivo activity against sepsis. Molecules. 2019;24:1702. doi: 10.3390/molecules24091702. PubMed DOI PMC

Courtens C., Risseeuw M., Caljon G., Maes L., Martin A., Van Calenbergh S. Amino acid based prodrugs of a fosmidomycin surrogate as antimalarial and antitubercular agents. Bioorg. Med. Chem. 2019;27:729–747. doi: 10.1016/j.bmc.2019.01.016. PubMed DOI

Jomaa H., Wiesner J., Sanderbrand S., Altincicek B., Weidemeyer C., Hintz M., Türbachova I., Eberl M., Zeidler J., Lichtenthaler H.K., et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science. 1999;285:1573–1576. doi: 10.1126/science.285.5433.1573. PubMed DOI

Ruangweerayut R., Looareesuwan S., Hutchinson D., Chauemung A., Banmairuroi V., Na-Bangchang K. Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria. Malaria J. 2008;7:225. doi: 10.1186/1475-2875-7-225. PubMed DOI PMC

Su X., Yi Y., Yan Z., Rosen B.H., Liang B., Winter M.C., Evans I.A., Rotti P.H.G., Yu Y., Gray J.S., et al. In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis. Sci. Trans. Med. 2019:eaau7531. doi: 10.1126/scitranslmed.aau7531. PubMed DOI PMC

Smith B.E., Wang S.L., Jaime-Figueroa S., Harbin A., Wang J., Hamman B.D., Crews C.M. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. Nat. Commun. 2019;10:131. doi: 10.1038/s41467-018-08027-7. PubMed DOI PMC

Lyu J., Wang S., Balius T., Singh I., Levit A., Moroz Y.S., O’Meara M.J., Che T., Algaa E., Tolmachova K., et al. Ultra-large library docking for discovering new chemotypes. Nature. 2019;566:224. doi: 10.1038/s41586-019-0917-9. PubMed DOI PMC

Liu R., Yue Z., Tsai C.-C., Shen J. Assessing lysine and cysteine reactivities for designing targeted covalent kinase inhibitors. J. Am. Chem. Soc. 2019;141:6553–6560. doi: 10.1021/jacs.8b13248. PubMed DOI PMC

Murugaiah A.M., Subbaiah S.M., Sridhar D., Thangeswaran R., Lakshumanan S., Mathiazhagan A., Salil D., Desai S.S., Susan M., Jenkins M.R., et al. Design, synthesis, and pharmacokinetic evaluation of phosphate and amino acid ester prodrugs for improving the oral bioavailability of the HIV-1 protease inhibitor atazanavir. J. Med. Chem. 2019;62:3553–3574. PubMed

Stoneman M.R., Biener G., Ward R.J., Pediani J.D., Badu D., Eis A., Popa I., Milligan G., Raicu V. A general method to quantify ligand-driven oligomerization from fluorescence-based images. Nat. Methods. 2019 May; doi: 10.1038/s41592-019-0408-9. PubMed DOI PMC

Boosani C.S., Agrawal D.K. PTEN modulators: A patent review. Expert Opin. Ther. Pat. 2013;23:569–580. doi: 10.1517/13543776.2013.768985. PubMed DOI PMC

Lee Y.R., Chen M., Lee J.D., Zhang J., Lin S.Y., Fu T.M., Chen H., Ishikawa T., Chiang S.Y., Katon J., et al. Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. Science. 2019;364:eaau0159. doi: 10.1126/science.aau0159. PubMed DOI PMC

Li L., Ma L., Wang D., Jia H., Yu M., Gu Y., Shang H., Zou Z. Design and synthesis of matrine derivatives as novel anti-pulmonary fibrotic agents via repression of the TGFβ/Smad pathway. Molecules. 2019;24:1108. doi: 10.3390/molecules24061108. PubMed DOI PMC

Fan R., Chuan D., Hou H., Chen H., Han B., Zhang X., Zhou L., Tong A., Xu J., Guo G. Development of a hybrid nanocarrier-recognizing tumor vasculature and penetrating the BBB for glioblastoma multi-targeting therapy. Nanoscale. 2019 Jun 5; doi: 10.1039/C9NR01320B. PubMed DOI

Wu Y., Beilei W., Junjie W., Shuang Q., Fengming Z., Ziping Q., Feiyang L., Qingwang L., Cheng C., Chen H., et al. Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a novel orally available potent inhibitor against broad-spectrum mutants of c-KIT kinase for gastrointestinal stromal tumors. J. Med. Chem. 2019 doi: 10.1021/acs.jmedchem.9b00280. PubMed DOI

Connelly C.M., Numata T., Boer R., Moon M.H., Sinniah R.S., Barchi J.J., Ferré-D’Amaré A.R., Schneekloth J.S., Jr. Synthetic ligands for PreQ1 riboswitches provide structural and mechanistic insights into targeting RNA tertiary structure. Nat. Commun. 2019;10:1501. doi: 10.1038/s41467-019-09493-3. PubMed DOI PMC

Andrei S.A., Sijbesma E., Hann M., Davis J., O’Mahony G., Perry M.W., Karawajczyk A., Eickhoff J., Brunsveld L., Doveston R.G., et al. Stabilization of protein-protein interactions in drug discovery. Expert Opin. Drug Discov. 2017;12:925–940. doi: 10.1080/17460441.2017.1346608. PubMed DOI

Sijbesma E., Hallenbeck K.K., Leysen S., de Vink P.J., Skóra L., Jahnke W., Brunsveld L., Arkin M.R., Ottmann C. Site-directed fragment-based screening for the discovery of protein-protein interaction stabilizers. J. Am. Chem. Soc. 2019;141:3524–3531. doi: 10.1021/jacs.8b11658. PubMed DOI

Koh A., De Vadder F., Kovatcheva-Datchary P., Backhed F. From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. Cell. 2016;165:1332–1345. doi: 10.1016/j.cell.2016.05.041. PubMed DOI

Luu M., Pautz S., Kohl V., Singh R., Romero R., Lucas S., Hofmann J., Raifer H., Vachharajani N., Carrascosa L.C., et al. The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic epigenetic crosstalk in lymphocytes. Nat. Commun. 2019;10:760. doi: 10.1038/s41467-019-08711-2. PubMed DOI PMC

Saidi L., Rocha D.H.A., Talhi O., Bentarzi Y., Nedjar-Kolli B., Bachari K., Almeida Paz F.A., Helguero L.A., Silva A.M.S. Synthesis of benzophenones and in vitro evaluation of their anticancer potential in breast and prostate cancer cells. ChemMedChem. 2019;14:1041–1048. doi: 10.1002/cmdc.201900127. PubMed DOI

Rossi A., Roviezzo F., Sorrentino R., Riemma M.A., Cerqua I., Bilancia R., Spaziano G., Troisi F., Pace S., Pinto A., et al. Leukotriene-mediated sex dimorphism in murine asthma-like features duringallergensensitization. Pharmacol. Res. 2019;139:182–190. doi: 10.1016/j.phrs.2018.11.024. PubMed DOI

Pace S., Pergola C., Dehm F., Rossi A., Gerstmeier J., Troisi F., Pein H., Schaible A.M., Weinigel C., Rummler S., et al. Androgen-mediated sex bias impairs efficiency of leukotriene biosynthesis inhibitors in males. J. Clin. Investig. 2017;127:3167–3176. doi: 10.1172/JCI92885. PubMed DOI PMC

Pace S., Rossi A., Krauth V., Dehm F., Troisi F., Bilancia R., Weinigel C., Rummler S., Werz O., Sautebin L. Sex differences in prostaglandin biosynthesis inneutrophils during acute inflammation. Sci. Rep. 2017;7:3759. doi: 10.1038/s41598-017-03696-8. PubMed DOI PMC

Trost B.M., Xu S., Sharif E.U. New catalytic asymmetric formation of oxygen heterocycles bearing nucleoside bases at the anomeric carbon. J. Am. Chem. Soc. 2019 doi: 10.1021/jacs.9b06050. PubMed DOI

Birkinshaw R.W., Gong J.N., Luo C.S., Lio D., White C.A., Anderson M.A., Blombery P., Lessene G., Majewski I.J., Thijssen R., et al. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nat. Commun. 2019;10:2385. doi: 10.1038/s41467-019-10363-1. PubMed DOI PMC

Casara P., Davidson J., Claperon A., Le Toumelin-Braizat G., Vogler M., Bruno A., Chanrion M., Lysiak-Auvity G., Le Diguarher T., Starck J.B., et al. S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget. 2018;9:20075–20088. doi: 10.18632/oncotarget.24744. PubMed DOI PMC

Zoppi V., Hughes S.J., Maniaci C., Testa A., Gmaschitz T., Wieshofer C., Koegl M., Riching K.M., Daniels D.L., Spallarossa A., et al. Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel-Lindau (VHL) based dual degrader probe of BRD9 and BRD7. J. Med. Chem. 2019;62:699–726. doi: 10.1021/acs.jmedchem.8b01413. PubMed DOI PMC